<DOC>
	<DOCNO>NCT00284271</DOCNO>
	<brief_summary>This study design test ( 1 ) feasibility efficiancy new BACOPP regimen ( 2 ) toxicity , overall response FFTF .</brief_summary>
	<brief_title>Feasibility Efficacy BACOPP-21 Patients &gt; 60 Years With Intermediate Advanced Hodgkins Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Hodgkin´s lymphoma ( histologically proven ) CS ( PS ) I II one risk factor ad 1. bulky mediastinal mass ( &gt; 1/3 maximum transverse thorax diameter ) 2. extranodal involvement 3 . ESR &gt; 50 ( A ) , &gt; 30 ( Bsymptoms ) 4 . 3 lymph node area involve CS ( PS ) III IV Written inform consent Leukocytes &lt; 3000/microl Platelets &lt; 100000/microl Hodgkin´s Disease `` composite lymphoma '' Activity index ( WHO ) &lt; grade 2</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Hodgkin´s Lymphoma</keyword>
	<keyword>eldery patient</keyword>
	<keyword>primary diagnosis</keyword>
</DOC>